IL2 and tuberculosis: In an MDR‐TB mouse model, immunotherapy with IL‐2 and GM‐CSF can improve the survival rate of mice, reduce bacterial loads in the lungs, spleen, and lesions, and enhance the efficacy of first‐line anti‐TB drugs.196